Cho BC, et al. WCLC 2016
CERITINIB: Korean Ph2 Study
Best response*, n
(%)
All (N= 32)
Crizotinib-
naïve (N= 30)
CR
1 (3)
1 (3)
PR
19 (59)
19 (59)
SD
6 (19)
6 (19)
PD
2 (6)
2 (6)
Not evaluable**
4 (6)
2 (7)
Overall response
rate, n (%)
20 (62)
20 (67)
Disease control
rate, n (%)
26 (81)
26 (87)
Duration of
response, months
18.4 (8.0-18.4)
N=8 pts CNS disease
ORR=25% DCR=63%
PFS all population=10 months
PFS crizo naive=20,7 months
Toxicity profile of Ceritinib
Diarrea (78%), nausea (63%)
and Anorexia (59%)
